1. EVITA: PHASE I/II STUDY OF EVEROLIMUS PLUS ITACITINIB IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA. (12th June 2019) Authors: Svoboda, J.; Barta, S.; Nasta, S.; Landsburg, D.; Gerson, J.; Ruella, M.; Waite, T.; King, C.; Emanuel, S.A.; Ballard, H.; Schuster, S. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 573 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PHASE I/II STUDY OF UMBRALISIB (TGR‐1202) IN COMBINATION WITH UBLITUXIMAB (TG‐1101) AND PEMBROLIZUMAB IN PATIENTS WITH REL/REF CLL AND RICHTER'S TRANSFORMATION. (12th June 2019) Authors: Mato, A.R.; Svoboda, J.; Luning Prak, E.T.; Schuster, S.J.; Tsao, P.Y.; Dorsey, C.; Sarmasti, L.M.; Becker, P.S.; Brander, D.M.; Nasta, S.; Landsburg, D.J.; King, C.M.; Morrigan, B.; Elwell, J.; Kennard, K.; Roeker, L.; Zelenetz, A.D.; Purdom, M.; Paskalis, D.; Sportelli, P. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 119 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗